Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.
Phase 2
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT00043446
- Lead Sponsor
- Tularik
- Brief Summary
The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does T900607-sodium target in ovarian neoplasms?
How does T900607-sodium compare to standard-of-care treatments for recurrent ovarian cancer?
Which biomarkers correlate with response to T900607-sodium in Tularik's phase 2 ovarian cancer trial?
What adverse events are associated with T900607-sodium in previously treated ovarian cancer patients?
Are there combination therapies involving T900607-sodium for high-grade serous ovarian carcinoma?
Trial Locations
- Locations (5)
Scripps Health Center
🇺🇸La Jolla, California, United States
USC Women's and Children's Hospital
🇺🇸Los Angeles, California, United States
University of California San Francisco
🇺🇸San Francisco, California, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Roswell Park Cancer Center
🇺🇸Buffalo, New York, United States
Scripps Health Center🇺🇸La Jolla, California, United States